RayzeBio Stock

rayzebio.comHealthcareFounded: 2020Funding to Date: $397.75MM

RayzeBio develops novel peptide mimetic binders to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter.

Register for Details

For more details on financing and valuation for RayzeBio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for RayzeBio.

Register Today

RayzeBio investors also invested in these private companies

Team

Management Team

Ken Song, MD
President & Chief Executive Officer
Susan Moran, MD, MSCE
Chief Medical Officer
Arvind Kush
Chief Financial Officer
Kimberly Ma, MS
Senior Vice President, Clinical Operations
Eric Cischoff
Senior Vice President, Development and Operations
Aubrey Haddach, JD
General Counsel & Secretary
Abhi Bhat, PhD
Senior Vice President Chemistry, Head of Discovery
Nicholas Smith, PhD
Senior Vice President, Chemistry Innovation
Gary G. Li, PhD
Senior Vice President, Biology & Translational Medicine

Board Members

Bong Koh
Venrock
Maha Katabi
Sofinnova Investments
Aaron Kantoff
Investment Partner
Aaron Royston
venBio Partners
Jerel Davis
Versant Ventures
Mike Dybbs
Samsara Capital

Other companies like RayzeBio in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

Ever since its launch in 2020, RayzeBio has talked at length about building a platform company to fulfill the potential that radiopharmaceuticals hold — with seven active programs to boast. But it’s stayed mum about what those programs actually are, instead sticking to updates about new funding, hires or partnerships.